Positive Survival Results from Apatorsen Phase II Trial in Metastatic Bladder Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OncoGenex Pharmaceuticals Inc. announced today positive survival results from the final analysis of the phase II Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

FDA approved Imfinzi (durvalumab)​ in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. 
The European Commission has granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer in the European Union, regardless of cisplatin eligibility.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login